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Myeloperoxidase (MPO) catalyzes the reaction of hydrogen peroxide with chloride ion to produce hypochlo-
rous acid (HOCl), which is used for microbial killing by phagocytic cells. Despite the important role of MPO
in host defense, however, MPO deficiency is relatively common in humans, and most of these individuals are
in good health. To define the in vivo role of MPO, we have generated by gene targeting mice having no MPO
activity in their neutrophils and monocytes. The mice without MPO developed normally, were fertile, and
showed normal clearance of intraperitoneal Staphylococcus aureus. However, they showed increased suscepti-
bility to pneumonia and death following intratracheal infection with Candida albicans. Furthermore, the lack
of MPO significantly enhanced the dissemination of intraperitoneally injected C. albicans into various organs
during the first 7 days. Thus, MPO is important for early host defense against fungal infection, and the
inability to generate HOCl cannot be compensated for by other oxygen-dependent systems in vivo in mice. The
mutant mice serve as a model for studying pulmonary and systemic candidiasis.
Neutrophil granulocytes are the first line of defense against
invading microorganisms such as bacteria, viruses, and fungi.
Apart from other defense mechanisms (4), the generation of
reactive oxygen compounds plays an important role in defense.
Myeloperoxidase (MPO; EC 1.11.1.7) is a cationic heme-con-
taining enzyme found in primary azurophilic granules of neu-
trophils and primary lysosomes of monocytes (3, 23). In che-
moattractant-activated neutrophils, MPO transforms hydrogen
peroxide (H2O2) generated during the oxidative burst to highly
cytotoxic hypochlorous acid (HOCl) in the presence of chlo-
ride ion (Cl2) (2). This MPO-H2O2-Cl
2 system appears to be
important in microbial killing by neutrophils (6, 22, 24, 35, 37,
52, 53). It may also be involved in their cytotoxicity against
tumor cells (7, 31) and in tissue damage at sites of inflamma-
tion, where neutrophils can release both MPO and H2O2 (5,
10–12, 18).
Both human MPO and murine MPO are encoded by a single
gene (Mpo in mice) (39, 54), and the respective genes have
been cloned and sequenced (19, 46). MPO is synthesized in
bone marrow during the late myeloblastic and promyelocytic
stages of myeloid maturation (55). MPO isolated from mature
human neutrophils has a molecular mass of 150 kDa and is
composed of two heavy chains (59 kDa) and two light chains
(14 kDa) (1, 36, 51).
Hereditary MPO deficiency appears to be the most common
biochemical defect of neutrophils and is not geographically
restricted (6, 22, 31, 34, 37, 40, 41, 43). An estimated preva-
lence of 1 of 2,000 to 4,000 individuals has been reported in the
United States (37) and Italy (8). Considering the important
role of HOCl for effective killing of microorganisms, it is sur-
prising that most individuals with MPO deficiency are healthy.
This fact stands in marked contrast to the situation for patients
with chronic granulomatous disease (CGD), in whom granu-
locytes are deficient in NADPH oxidase and consequently do
not produce any reactive oxygen compound. Patients with
CGD typically have clinical symptoms early in life and recur-
rent infections that can lead to death during childhood. How-
ever, an increased susceptibility to infections, particularly those
caused by Candida albicans, has been reported for some MPO-
deficient patients (6, 29, 35, 37). In these patients, who were
also affected with diabetes, it was not determined whether the
infections were due to MPO deficiency or whether other dis-
orders were also relevant. An interplay of other mechanisms
seems to compensate for the inability of MPO-deficient cells to
generate HOCl from H2O2.
Here, we report the generation of mice with a nonfunctional
allele for MPO by targeted homologous recombination with
mouse ES cells. The enzyme activity of MPO is absent in
neutrophils and monocytes from homozygous mutant mice.
These mice also exhibit increased susceptibility to infection
with C. albicans.
MATERIALS AND METHODS
Cloning of the mouse Mpo gene and construction of a targeting vector. A
396-bp DNA fragment containing exons 5 and 6 of the mouse Mpo gene was
amplified from ES cell genomic DNA with primers designed from the published
sequence (46). This fragment was used as a probe to screen a l phage library
made from strain 129 mouse genomic DNA. A clone containing a part of the
Mpo gene was isolated, and its restriction map and a partial nucleotide sequence
were determined. For constructing the targeting vector (Fig. 1A), a 2.2-kb frag-
ment containing exons 1 to 5 and a 5.9-kb fragment containing exons 8 to 11 were
used as the two homologous arms flanking the neo gene. The herpes simplex
virus (HSV) thymidine kinase (TK) gene was positioned downstream of the
longer arm (32).
Gene targeting and production of mice by use of modified ES cells. BK4 cells,
a subclone of E14TG2a derived from strain 129/Ola mice, were cultured on
feeder cells as described previously (44). The targeting vector mentioned above
was linearized with NotI and introduced into ES cells by electroporation. Colo-
nies doubly resistant to G418 (200 mg/ml) and ganciclovir (2 mM) were screened
for homologous recombination by Southern blot analysis following digestion of
genomic DNA with BglII by use of the 722-bp PCR-amplified fragment contain-
ing exon 5 of the Mpo gene as a probe. The resulting cells with a disrupted Mpo
gene were injected into blastocysts to obtain chimeras as described previously
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(25, 47). Animals classified as chimeric by coat color were mated with strain
C57BL/6 mice, and F1 animals heterozygous for the disrupted Mpo gene were
obtained. Interbreeding of heterozygous offspring was used to produce mice
homozygous for the modified MPO allele.
Northern blotting of bone marrow cells. Total RNA was isolated from bone
marrow cells with TRIzol (Gibco BRL) as recommended by the manufacturer.
Each sample (10 mg) was electrophoresed in a 2.2 M formaldehyde–1% agarose
gel, transferred to a Hybond nylon membrane (Amersham Corp.), and probed
with a 2.2-kb PstI fragment of a human MPO cDNA vector (pH17) (17) con-
taining exons 2 through 12 of the MPO gene. This fragment is 85% identical to
that in mouse cDNA. A cDNA clone for chicken b-actin was used as a probe to
evaluate the amount of mRNA loaded. mRNA levels were estimated by densi-
tometric analysis of autoradiograms after serial exposures.
Cell counting and measurement of MPO activity. Blood was drawn from the
retro-orbital plexus of mice into EDTA-containing tubes. Blood cell analysis was
carried out by flow cytometry with Technicon H-1 by the method recommended
by the manufacturer. Briefly, separation of leukocytes was performed by perox-
idase staining and simultaneous measurement of light scattering (Perox-Chan-
nel). For peroxidase staining, erythrocytes were lsyed in the Technicon H-1-
integrated Perox-Chamber, and leukocytes were fixed with formalin and stained
for peroxidase with H2O2 and 4-chloro-1-naphthol as a chromogen. The cell
distribution pattern was plotted by a so-called leukogram with peroxidase activity
on the x axis and light scattering on the y axis and was analyzed by a multispecies
software program developed for animal blood samples. If intracellular MPO
activity decreases, neutrophils and monocytes shift to the left.
Thioglycolate-induced peritonitis. Mice were injected intraperitoneally with 1
ml of 3% fluid thioglycolate medium (Difco). After 4 h, peritoneal exudate cells
were harvested by peritoneal lavage with 20 ml of phosphate-buffered saline
(PBS). Total cell numbers were determined with a hemocytometer. The percent-
age of neutrophils was determined by microscopic examination of Wright-Gi-
emsa-stained samples.
Cytochemical and biochemical determination of MPO activity. Isolated neu-
trophil-rich peritoneal exudate cells were stained for MPO activity with the
3,39,5,59-tetramethylbenzidine (TMB) liquid substrate system from Sigma (St.
Louis, Mo.) following formalin-acetone fixation of the cells. Briefly, oxidation of
the substrate TMB in MPO-positive cells yields a blue insoluble reaction product
which is visualized by light microscopy. MPO activity was quantitatively mea-
sured by the method of Suzuki et al. (45) with some modifications. Peritoneal
exudate neutrophils were adjusted to 5 3 106 cells/ml and incubated with N-
formyl-Met-Leu-Phe (1 mM) and cytochalasin B (5 mg/ml) for 10 min at 37°C.
Triton X-100 (final concentration, 0.1%) was added to the cell suspensions for
total MPO release. Aliquots of the cell extracts were incubated with the TMB
liquid substrate system, and the oxidized product was detected spectrophoto-
metrically. The activity was expressed as the initial rate of increase in the absor-
bance at 655 nm.
Generation of HOCl and O2
2 from neutrophils. HOCl generation by perito-
neal exudate neutrophils was measured by the chlorination of monochlorodime-
don (MCD) (21). Peritoneal exudate cells (2 3 106/ml) were incubated in PBS
containing 1 mM CaCl2, 0.5 mM MgCl2, 5 mM glucose, 100 ng of phorbol
myrisate acetate (PMA) per ml, and 20 mM MCD at 37°C for 20 min. At the end
of this period, samples were ice chilled and centrifuged at 12,000 3 g for 5 min.
The activity in supernatants of reaction mixtures with or without cells was
measured at 290 nm. The amount of HOCl generated was calculated by use of
a molar linear absorption coefficient of 19,000 M21/cm (16).
O22 generation was determined as the superoxide dismutase (SOD)-inhibit-
able reduction of cytochrome c (14). Cytochrome c (40 mM) with or without 20
mg of SOD per ml was added to peritoneal exudate cells (2 3 106/ml) that had
been stimulated with 100 ng of PMA per ml at 37°C for 5 min, and O22
generation in the samples was continuously measured for another 5 min at 550
nm with a spectrophotometer. O22 generated from the cells was calculated as the
difference between levels in SOD-containing samples and those in samples not
containing SOD by use of an absorption coefficient of 21,000 M21/cm (14).
Experimental infections with C. albicans and Staphylococcus aureus. Stock
cultures of C. albicans (ATCC 18804) were cultured on 2% agar slant medium
(pH 6.4) containing 83 mM glucose, 2 mM MgSO4 z 7H2O, 7.4 mM KH2PO4,
0.5% Polypeptone, and 0.2% yeast extract for 10 days at 37°C. Blastoconidia of
C. albicans grown on the slant were transferred to 1.2% agar plates containing 28
mM glucose and 0.2% Polypeptone. After cultivation for 2 days at 37°C, the
blastoconidia were harvested in sterile saline. The number of fungi was counted
with a hemocytometer and adjusted to 2 3 108 cells/ml; the viable number was
also determined by plating the diluted samples on agar plates. Wild-type, het-
erozygous, and homozygous mutant mice were injected by the intratracheal route
with 0.02 ml of the fungal suspension. At 0.5, 20, 80, and 120 h after the
challenge, the organs were removed aseptically and homogenized in sterile sa-
line. At least five mice were used per group. Aliquots of the homogenates were
plated in duplicate on agar plates with Guanofuracin-Sabouraud medium (Eiken
Chemical Co., Tokyo, Japan) and incubated for 48 h at 37°C. The number of
viable C. albicans was calculated from the number of colonies grown on the
plates and was expressed in CFU. Data were recorded as the mean log10 CFU
per organ.
In studies of systemic infections, wild-type and homozygous mutant mice were
injected intraperitoneally with 4 3 106 cells of C. albicans. Seven days later, the
organs were removed, homogenized, and plated on agar plates as described
above. Five mice were used per group.
For intraperitoneal infection with S. aureus, mice were injected intraperitone-
ally with 0.1 ml of a suspension (7 3 108/ml) of S. aureus (FDA209P) that had
been grown for 24 h on a plate with Trypticase soy agar at 37°C. Twenty-four and
48 h later, peritoneal exudate fluid was harvested with PBS, diluted, and cultured
for viable S. aureus on Trypticase soy agar at 37°C. Three to five mice of different
genotypes were studied at each time point.
Preparation of sections and slides. Lungs were fixed in a buffered 4% para-
formaldehyde solution, dehydrated in ethanol, and embedded in paraffin for
sectioning. Sections were prepared, and hematoxylin and eosin (H&E) staining
and Grocott staining were carried out by standard protocols.
RESULTS
Targeted disruption of the mouse Mpo gene. The targeting
strategy used to disrupt the Mpo coding sequence is illustrated
FIG. 1. Targeted disruption of the mouse Mpo gene and germ line transmis-
sion of the disrupted allele. (A) Structures of the wild-type Mpo locus, targeting
vector, and mutant allele generated by homologous recombination. Exons are
shown as black boxes and numbered. The targeting vector contains the neo gene
(NEO) in place of the XbaI-EcoRI region containing exons 6 and 7. The HSV
TK gene is attached to the end of the region of homology. The broken line
indicates the vector sequence. The lengths of diagnostic BglII restriction frag-
ments and the location of a probe used for Southern blot analysis are shown. B,
BamHI; Bg, BglII; E, EcoRI; N, NotI; X, XbaI. (B) Southern blot analysis.
Genomic DNA was isolated from tail snips of the offspring of a heterozygous
cross, digested with BglII, and analyzed by Southern hybridization with the DNA
probe indicated in panel A. Genotypes are indicated as wild-type (1/1), het-
erozygous (1/2), and homozygous (2/2) mice. (C) Northern blot analysis of
bone marrow mRNA. Total RNA (10 mg) isolated from bone marrow of wild-
type (1/1), heterozygous mutant (1/2), and homozygous mutant (2/2) mice
was electrophoresed, blotted, and hybridized to a human MPO cDNA probe. The
amounts of RNA loaded are indicated by hybridization to a cDNA probe for
chicken b-actin.
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in Fig. 1A. The targeting vector was constructed by removing a
0.7-kb XbaI-EcoRI fragment containing exon 6 through a part
of intron 7 and replacing it with the neo gene. In addition, a
copy of the HSV TK gene was placed at the 39 end of the
construct. Both of the selectable marker genes were inserted in
the same transcriptional orientation as the Mpo gene. Male
chimeric mice generated by use of correctly targeted ES cells
transmitted the mutation of the Mpo gene through the germ
line when mated with C57BL/6 female mice (Fig. 1B). Hetero-
zygote (Mpo1/2) mating then produced homozygous mutant
mice (Mpo2/2) at the expected Mendelian frequency. The
mutant mice were viable, exhibited normal growth and devel-
opment, and were fertile. As shown in Fig. 1C, Northern blot
analysis of mRNA isolated from the bone marrow of homozy-
gous mutant mice showed no significant hybridization to the
human MPO cDNA probe, whereas the bone marrow of wild-
type mice (Mpo1/1) contained mRNA for Mpo, indicating the
absence of any detectable transcript for the Mpo gene in the
mutants. The heterozygous mice showed the expected 50%
reduction in mRNA levels.
Identification of MPO-deficient neutrophils and monocytes.
Figure 2 shows the leukograms for the peroxidase activity of
peripheral blood cells from wild-type and homozygous mutant
mice determined with Technicon H-1. When stained vesicles
are lacking, the light scattering changes characteristically, lead-
ing to a cluster location upward on the y axis and a shift to the
left on the x axis. The neutrophil clusters from homozygous
mutant mice clearly shifted to the left, unstained cell area, and
no stained cells were observed in the normal neutrophil area.
The mutant mice also showed no clusters in the monocyte area.
These results strongly suggested that the neutrophils and the
monocytes of the homozygous mice that we generated are
completely deficient in MPO. However, the clusters of their
eosinophils did not shift to the left, demonstrating that eosin-
ophil peroxidase is genetically distinct from MPO.
MPO activity in peritoneal exudate neutrophils. In order to
explore MPO deficiency in further detail, neutrophils were
isolated from the thioglycolate-injected peritoneal cavity of
wild-type, heterozygous, and homozygous mice. Judging from
the microscopic examination of Wright-Giemsa-stained sam-
ples, more than 95% of the exudate cells recovered 4 h after
injection were neutrophils, regardless of their genotypes. Cy-
tochemical staining with TMB revealed that more than 95% of
the exudate cells in wild-type and heterozygous mice were
peroxidase positive (Fig. 3A). In contrast, the majority of ho-
mozygous mutant mice were peroxidase negative. Quantitative
analysis by spectrophotometry demonstrated that the average
MPO activity in wild-type mice was 1.7 nmol/min/106 cells (Fig.
3B). Heterozygous animals showed the expected 50% reduc-
tion in MPO activity. Homozygous mutant mice showed only a
low level of MPO activity. This low level of activity likely
represents peroxidase activity supplied by eosinophils, because
eosinophil peroxidase is normally active in homozygous mutant
mice (Fig. 2) and is able to oxidize TMB. From these results,
we conclude that homozygous mutant mice have no detectable
MPO activity, while heterozygous mice have half the level of
MPO activity present in wild-type littermates.
HOCl and O2
2 generation from normal and MPO-deficient
neutrophils. During the respiratory burst, neutrophils generate
FIG. 2. Leukograms of Technicon H-1 analysis of wild-type (1/1) and ho-
mozygous mutant (2/2) mice. Light scattering is plotted on the y axis, and
peroxidase (PEROX) activity is plotted on the x axis. The numbers indicate the
following cells: 1, lymphocytes; 2, monocytes; 3, neutrophils; 4, eosinophils. The
lower the peroxidase activity of a single cell, the more the cell is located toward
the left on the x axis. Histograms of peroxidase activity are shown below the
graphs.
FIG. 3. MPO activity of neutrophils. Wild-type (1/1), heterozygous mutant (1/2), and homozygous mutant (2/2) mice were injected with thioglycolate in the
peritoneal cavity, and peritoneal exudate cells were collected 4 h later. (A) The cells were fixed and stained with TMB for peroxidase activity. (B) Peroxidase activities
in total peritoneal exudate cells were measured with TMB as a substrate. Three animals of different genotypes, each tested in duplicate, were used. Results represent
means 6 standard deviations.
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O2
2 via the NADPH oxidase system. O2
2 is then reduced to
H2O2, from which HOCl is generated by the MPO reaction.
The rapid reaction of MCD with HOCl to form dichlo-
rodimedon (21) was used to determine the level of HOCl
generation from the peritoneal exudate neutrophils (Fig. 4).
The average level of HOCl generation from wild-type neutro-
phils was 0.47 nmol/min/106 cells. On the other hand, as an-
ticipated from the absence of peroxidase activity (Fig. 2 and 3),
the neutrophils of homozygous mutant mice produced HOCl
at an almost undetectable level. Because EPO also produces
HOCl from H2O2, a low level of HOCl detected in homozy-
gous mutant mice could be supplied from eosinophils. The
neutrophils of heterozygous mutant mice generated from half
the normal level of HOCl. These results demonstrate that the
levels of HOCl generated from the neutrophils in each geno-
type correlate well with the MPO activities measured with
TMB as a substrate (Fig. 3).
O2
2 generation by peritoneal exudate neutrophils was mea-
sured as SOD-inhibitable cytochrome c reduction. The average
level of O2
2 generation from neutrophils of wild-type mice was
0.39 nmol/min/106 cells (Fig. 4) and was completely inhibited
in the presence of SOD (data not shown). The neutrophils of
homozygous mutant mice generated a slightly higher level of
O2
2 (0.50 nmol/min/106 cells) than did those of wild-type mice
(P, ,0.05) (Fig. 4). A slight enhancement of O2
2 generation
was also seen in heterozygous mutant mice, although it did not
reach statistical significance (P, 0.075).
Clearance of S. aureus in vivo. To assess whether MPO-
deficient mice have enhanced susceptibility to S. aureus infec-
tion in vivo, mice were intraperitoneally challenged with 7 3
107 cells of S. aureus. Most of the cells injected disappeared by
48 h both in wild-type and in homozygous mutant mice, and
there was no difference in the rates of clearance between those
mice (Fig. 5). Gross anatomical experiments revealed no ob-
vious inflammation of the lungs, liver, heart, kidneys, and in-
testines.
Pulmonary infection with C. albicans. To investigate the
susceptibility of MPO-deficient mice to C. albicans compared
to that of wild-type littermates, 26 wild-type, 18 heterozygous
mutant, and 27 homozygous mutant mice were challenged with
4 3 106 fungi intratracheally. This is a relatively low dose, since
the 50% lethal dose for mice challenged by the intratracheal
route was estimated to be in excess of 108 yeast cells by Sawyer
(42). On the following day, signs of severe infection, including
ruffled fur and hunched posture, were observed only in the
homozygous mutant mice. The wild-type mice were able to
eliminate the fungi effectively, and approximately 2,000 fungi
were recovered from their lungs 120 h after infection (Fig. 6A).
In contrast, in the mutant mice, the clearance of viable C.
albicans was significantly delayed, and nearly 500 times as
many viable fungi were cultured from their lungs (Fig. 6A). In
addition, the survival of the mutant mice was dramatically
decreased, and 18 of the 27 mice died by 5 days after the
challenge. We also determined the numbers of viable C. albi-
cans cultured from other tissues. In the kidneys (Fig. 6B), the
number of C. albicans in the wild-type mice was almost below
the detectable level, whereas that in the homozygous mutant
mice was time dependently increased, and about 6,000 fungi
were detected at 120 h. In the brain, heart, and liver of both
wild-type and homozygous mutant mice, the numbers of C.
albicans were all below 100 fungi per each organ from 20 to
120 h. C. albicans was not detectable in the spleen. There was
no difference in the numbers of viable fungi obtained from the
mutant mice that had died or that had been weakened. Al-
though the clearance of fungi from the lungs in the heterozy-
gous mutant mice was slightly delayed at 80 h compared to that
in the wild-type mice, almost the same number of fungi disap-
peared by 120 h (Fig. 6A).
Only one wild-type mouse died 3 days after the challenge as
a consequence of lung bleeding, but no gross or histological
abnormalities were observed in the lungs of this mouse or
those of the wild-type mice still alive by 120 h (Fig. 7A and B).
In contrast, the lungs of the mutant mice 120 h after the
challenge showed diffuse enlargement and brownish discolor-
ation (Fig. 7A). Additionally, patchy white, soft, and spherical
masses 1 to 5 mm in diameter were observed on the surfaces of
every lobe (Fig. 7A). H&E-stained sections of the lungs re-
vealed massive infiltration of alveolar and peribronchiolar
spaces with neutrophil polymorphonuclear leukocytes, and
FIG. 4. HOCl and O22 generation from neutrophils of wild-type (1/1),
heterozygous mutant (1/2), and homozygous mutant (2/2) mice. The levels of
HOCl (closed bars) and O22 (open bars) generated from PMA-stimulated peri-
toneal exudate neutrophils (2 3 105 cells) were determined by the chlorination
of MCD and the SOD-inhibitable reduction of cytochrome c, respectively. Three
animals of each genotype were used in each experiment, and assays were per-
formed in triplicate. Results represent means 6 standard deviations. The asterisk
indicates a P value of ,0.05 for mutant versus wild-type mice, as determined by
Student’s t test.
FIG. 5. Clearance of viable S. aureus from the peritoneal cavity. Peritoneal
exudate fluid was cultured 24 and 48 h after intraperitoneal injection of 7 3 107
CFU of S. aureus. Results represent mean log10 CFU 6 standard deviations
obtained from three to five wild-type mice (closed circles) and homozygous
mutant mice (open circles).
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fairly extensive edema filled many other alveolar spaces (Fig.
7C). In peribronchiolar spaces around neutrophil infiltrates,
mucus infiltration was also observed. Furthermore, some of the
peribronchial epithelial cells were observed to be peeling off
(Fig. 7D). By Grocott staining, hyphae of C. albicans were
detected in several alveolar spaces of the mutant mice (Fig.
7E) but not the wild-type mice (data not shown). These clinical
features are characteristic of alveolar and peribronchiolar
pneumonia, and the most likely explanation for the death of
the mutant mice infected with C. albicans is severe impairment
of lung functions caused by myeloid cell infiltration and edema.
Systemic infection with C. albicans via the intraperitoneal
route. To evaluate the susceptibility of wild-type and MPO-
deficient mice, C. albicans was administered intraperitoneally
at a dose of 4 3 106 fungi/mouse. Seven days later, the lungs,
brain, kidneys, spleen, and liver were removed from five ani-
mals in each group and pooled to determine the dissemination
of the fungi into these organs. Gross anatomical evaluation
revealed no obvious inflammation in any of those organs. In
the wild-type mice, the highest and lowest numbers of fungi
were found in the liver and the brain, respectively (Fig. 8),
consistent with a previous report (20). In contrast, significantly
higher numbers of fungi were disseminated into every organ in
the homozygous mutant mice, and approximately 290, 11, 110,
17, and 10 times as many viable fungi were cultured from the
lungs, brain, kidneys, spleen, and liver, respectively (Fig. 8).
Unlike the results of the intratracheal infection, no obvious
signs of severe infection were observed in either wild-type or
homozygous mutant mice during a period of 7 days after the
challenge. When mice were challenged intraperitoneally at a
high dose (108 fungi/mouse), all homozygous mutant mice died
by 2 days, while all wild-type mice survived for 7 days without
many signs of distress. These results demonstrate that MPO is
very important for the murine host defense against C. albicans
and that the lack of MPO enhances C. albicans dissemination,
especially into the lungs and kidneys.
DISCUSSION
MPO-deficient mice generated by disruption of the Mpo
locus by homologous recombination represent the first genet-
ically defined model for the inherited human MPO deficiency.
The mutation disrupts the Mpo gene and completely eliminates
expression of the gene, as demonstrated by the absence of the
mRNA in the bone marrow and of enzyme activity in the
neutrophils and monocytes of homozygous mutant mice. No
HOCl generation by neutrophils in homozygous mutant mice
was observed. O2
2 generation was slightly increased in our
MPO-deficient mice, consistent with the deficiency in humans
(22, 41). Heterozygous mutant mice had half the normal levels
of mRNA, enzyme activity, and HOCl generation.
Homozygous mutant mice completely lacking MPO activity
are born and develop normally but exhibited markedly en-
hanced susceptibility to infection with C. albicans. Mutant mice
intratracheally exposed to even a low dose of C. albicans de-
veloped severe alveolar and peribronchiolar pneumonia (Fig.
7) resulting in the death of two-thirds of the mice. Although
this challenge was time dependently disseminated into the
kidneys (Fig. 6B), this process was unlikely to be the main
cause of death, because mice intraperitoneally infected with C.
albicans were in good health for at least 7 days even when a
slightly higher number of fungi was present in the kidneys (Fig.
8). Rather, the severe pneumonia was more likely to be the
main cause of death of the mutant mice intratracheally chal-
lenged with C. albicans. It is well known that MPO plus H2O2
plus Cl2 forms a cytotoxic triad in vitro which is toxic for fungi
(9, 49) and that neutrophils genetically deficient in MPO fail to
kill them (37). In addition, neutrophils are often the first cells
to be recruited to a site of infection, where they show a higher
level of phagocytic activity against C. albicans than do alveolar
macrophages (26). Taken together, the results indicate that it
is most plausible that neutrophils with MPO represent the
early stage of defense in the lungs against C. albicans and that
FIG. 6. Pulmonary infection with C. albicans in wild-type, heterozygous mutant, and homozygous mutant mice. Wild-type (closed circles), heterozygous mutant
(open triangles), and homozygous mutant (open circles) mice were injected intratracheally with 4 3 106 CFU of C. albicans. At the indicated times after the challenge,
whole lungs (A) and kidneys (B) were homogenized, and aliquots of the homogenates were plated on Guanofuracin-Sabouraud agar plates. Five mice or more were
used in each group. Results represent mean log10 CFU per organ 6 standard deviations.
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FIG. 7. Lung pathology observed in wild-type and homozygous mutant mice 120 h after intratracheal challenge with C. albicans. (A) Representative gross
appearance of lungs from wild-type (1/1) and homozygous mutant (2/2) mice. (B) H&E-stained section from a wild-type mouse. Magnification, 340. (C)
H&E-stained section from a representative homozygous mutant mouse. Magnification, 340. (D) Same sample as C but at a magnification of 3400. (E) Grocott-stained
section from a homozygous mutant mouse. Magnification, 3400.
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inefficient killing due to the lack of MPO causes a continuous
recruitment of neutrophils into the lungs, leading to congestion
of the lungs.
Heterozygous mice, having about half the normal level of
MPO activity (Fig. 3 and 4), showed only a slight delay in the
killing of C. albicans in the lungs compared to that in wild-type
mice at the tested dose (Fig. 6). These results strongly suggest
that HOCl produced from neutrophils at half the normal rate
could be sufficient in vivo for exhibiting complete fungal kill-
ing. Alternatively, neutrophils with normal and suboptimal
MPO activities may equally enhance secondary antifungal ef-
fector activities, such as that of macrophages. Although alve-
olar macrophages are less able to kill C. albicans than neutro-
phils (26), those exposed to MPO are known to exhibit an
enhanced respiratory burst (30), resulting in augmentation of
the macrophage-mediated cytotoxicity for C. albicans (28, 33).
Furthermore, MPO stimulates macrophages to secrete cyto-
kines, such as tumor necrosis factor alpha (27), which causes
neutrophils to degranulate and to release more MPO into the
microenvironment and which potentiates Candida killing by
neutrophils in vitro (13). Hence, a feedback loop is established
until the pathogen is removed. Further studies on the suscep-
tibility of heterozygous mice with strain backgrounds different
from 129/C57BL to various doses of fungi are important to
clarify the risk of patients with partial MPO deficiency for
fungal infection.
The increase in fungal load found in the lungs, brain, kid-
neys, spleen, and liver of systemically infected MPO-deficient
mice may imply a possible unique role for MPO against Can-
dida infection in each organ. Among the organs, the lungs and
the kidneys were most affected by the lack of MPO, while the
other organs were less affected. It has been reported that
depletion of neutrophils in mice increases the susceptibility to
systemic infection with C. albicans and that the fungal burden
in the kidneys increases 100-fold on day 4, while the brain is
little affected (15). Our results obtained with MPO-deficient
mice are similar to those obtained with neutrophil-depleted
mice (15). Furthermore, intraperitoneal administration of pu-
rified MPO has been reported to increase the resistance of
mice to Candida infection (50), suggesting that peritoneal neu-
trophils without MPO are impaired in their ability to protect
against invasion from the intraperitoneal route. Collectively,
these results indicate that neutrophils with MPO play a critical
role against systemic candidiasis, especially in the lungs and
kidneys, while other defense systems, such as the phagocytic
function of macrophages, appear to be more effective in the
brain, spleen, and liver.
When homozygous mutant mice were challenged with the
same dose of C. albicans (4 3 106 fungi/mouse) by different
routes (intratracheal and intraperitoneal), the mice showed a
higher level of resistance to challenge by the intraperitoneal
route, and no death occurred within 7 days. As peritoneal
macrophages have higher levels of phagocytic activity than do
alveolar macrophages (48), the mechanism of resistance may
be due to the presence of an environment rich in macrophage
activity in the area where the systemic invasion is prevented or
delayed by phagocytosis.
Homozygous mutant mice did not exhibit a remarkable dif-
ference from wild-type mice in the rate of clearance of S.
aureus from the peritoneal cavity (Fig. 5). This finding is con-
sistent with the fact that most humans deficient in MPO show
no symptoms and with the observations that although the in
vitro killing of S. aureus in MPO-deficient neutrophils is sig-
nificantly less effective than normal at early time periods, it
reaches the normal rate by approximately 1 h (37) or 2 h (22)
after the organism is ingested. The lack of impairment in the
clearance of S. aureus in our homozygous mutant mice in vivo
is also in clear contrast to the results obtained with a mouse
model of CGD; because of a mutation in the NADPH oxidase
gene, these mice are unable to generate O2
2, and the clear-
ance of S. aureus from the peritoneal cavity is retarded (38). It
is thus likely that reactive oxygen species other than HOCl,
such as O2
2, are sufficient for neutrophils to kill S. aureus.
Further studies with MPO-deficient mice are warranted to
define the role of MPO in S. aureus infection.
Oxidants generated by neutrophils and monocytes have been
implicated in the tissue damage that occurs when these phago-
cytic cells penetrate tissue in various chronic inflammatory
conditions (10–12). However, to date there is a lack of con-
vincing evidence that the MPO-H2O2-Cl
2 system causes tissue
injury in chronic inflammation in vivo. MPO-deficient mice
should therefore be invaluable for evaluating the role of
phagocyte-derived oxidants not only in host defense against
various pathogens but also in tissue injury and resolution of the
inflammatory response and for refining treatment strategies.
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FIG. 8. Numbers of C. albicans cultured from various organs of mice after
intraperitoneal challenge. Wild-type mice (closed bars) and homozygous mutant
mice (open bars) were injected intraperitoneally with 4 3 106 cells of C. albicans.
Seven days after the challenge, the organs were removed and homogenized, and
aliquots of the homogenates were plated on Guanofuracin-Sabouraud agar
plates. Five mice were used in each group. Results represent mean log10 CFU
per organ 6 standard deviations.
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